This study aims to evaluate the effect of statins combined with conventional chemotherapy and maintenance therapy on the prognosis of ovarian cancer patients, exploring its potential to improve survival rates and quality of life.
Participants must provide written informed consent before any trial procedures commence. The consent form must be documented and retained at the research center.
Female patients aged 18 years and older.
Patients diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (collectively referred to as ovarian cancer) through open surgery, laparoscopic surgery, or core needle biopsy confirmed by pathology.
Patients who will require neoadjuvant chemotherapy followed by direct surgery, or direct surgical chemotherapy.
Are using other investigational drugs or participating in other clinical drug trials simultaneously;
Have used or are currently using any medications that interact with statins;
Have active cirrhosis, uncontrolled concurrent diseases, a history of chronic myopathy, active hepatitis, or unexplained persistent elevation of serum aminotransferases;
Are known to be allergic to statins, or any active or inactive components of drugs with similar chemical structures;
Parallel
Statin
DrugStatin Group: Conventional chemotherapy and maintenance therapy combined with statins.
Sugar pill
DrugControl Group: Conventional chemotherapy and maintenance therapy alone.
Progression free survival
The time between the start of the trial and tumor progression (in any way) or death (from any cause)
Disease free survival
Time from surgical resection to local recurrence
Changes of tumor marker CA125
Changes in Serum CA125 from Enrollment to End of Trial
Changes of tumor marker HE4
Changes in Serum HE4 from Enrollment to End of Trial
Lipid change
Changes in Serum Lipid from Enrollment to End of Trial
Click on the lead sponsor to view all of their trials.
